Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Alembic Pharmaceuticals Limited
483
•Alembic Pharmaceuticals Limited•March 25, 2016

Alembic Pharmaceuticals Limited – FDA 483, Mar 25, 2016

Record Details

During an FDA inspection, several deficiencies were noted regarding quality control, documentation, and contamination prevention.

The quality control unit's procedures were not fully followed, specifically concerning a change to blister packaging machines. A piece of material prepared on-site was introduced to prevent vibration and pill ejection, but this change was not done according to established change control procedures, lacking review, evaluation, and approval by quality assurance. This modification's impact on product quality and potential for contamination is unclear.

Production and process control procedures were not documented contemporaneously. An operator initialed a "Challenge Test" as completed on a batch packaging record, but the test was still in progress on the blister pack line.

Procedures to prevent objectionable microorganisms in non-sterile drug products were inadequate. Air bubbles were observed during microbiological enumeration of samples, and the test procedure (APL/RT0122) lacked sufficient detail to prevent this. The environmental monitoring and swab sampling procedure (ALP/QC/SOP098) failed to include the use of specific media for yeast and mold testing in cleaning validation. A leak was observed from a pipe connecting a water storage tank, with no controls to prevent potential ingress of microorganisms.

Finally, deviation investigation #ALP/QA/DC6020 failed to thoroughly review an unexplained discrepancy. It did not assess other drug products potentially affected by a breach involving a damaged gasket and traveling material, failing to assure no product impact on prior batches.

Company
Alembic Pharmaceuticals Limited
Inspection date
March 25, 2016
Office
Division of Pharmaceutical Quality Operations IV
People
  • Erika V. Butler (Compliance Officer / Investigator)
  • Jason K. Morgan
  • Jeffrey D. Meng (Associate Director)
View Company Profile

ID · b5435c4b-1323-4172-9f87-3079d507645c

Violation Codes2
FD&C Act 801(a)(3)21 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Alembic Pharmaceuticals Limited
  • 483 - 2018-03-20March 20, 2018
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Alembic Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.